GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, a global biopharma company, covers transaction notifications for the month of December 2025. The report details share purchases made by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) on December 19 and December 22, 2025.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific insider trading transactions.
| Transaction Date | Individual | Role | Instrument | Volume | Price | Exchange |
|---|---|---|---|---|---|---|
| 2025-12-19 | Wendy Becker | Independent Non-Executive Director | Ordinary Shares | 441 | £18.0909 | London Stock Exchange |
| 2025-12-19 | Elizabeth (Liz) McKee Anderson | Independent Non-Executive Director | ADSs | 201 | $48.5550 | New York Stock Exchange |
| 2025-12-19 | Charles Bancroft | Senior Independent Non-Executive Director | ADSs | 1,577 | $48.5550 | New York Stock Exchange |
| 2025-12-19 | Dr Anne Beal | Independent Non-Executive Director | ADSs | 201 | $48.5550 | New York Stock Exchange |
| 2025-12-19 | Dr Hal Dietz | Independent Non-Executive Director | ADSs | 201 | $48.5550 | New York Stock Exchange |
| 2025-12-19 | Dr Jeannie Lee | Independent Non-Executive Director | ADSs | 202 | $48.5550 | New York Stock Exchange |
| 2025-12-19 | Dr Vishal Sikka | Independent Non-Executive Director | ADSs | 730 | $48.5550 | New York Stock Exchange |
| 2025-12-22 | Lady Susan Symonds | PCA of Sir Jonathan Symonds | Ordinary Shares | 1,650 | £18.1046 | London Stock Exchange |
Material Changes
The filing does not contain comparative financial data or material changes to the company's operations versus prior periods. It serves solely as a regulatory disclosure of recent insider purchases.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is limited to transaction notifications.
Key Facts for Investor Verification
- Insider Sentiment: Multiple Independent Non-Executive Directors and a PCA purchased shares on the same day (Dec 19) and shortly thereafter (Dec 22), indicating potential confidence in the company's direction.
- Transaction Consistency: All ADS purchases on December 19 occurred at the exact same price of $48.5550, suggesting a coordinated or market-driven execution.
- Currency Exposure: Transactions were split between the London Stock Exchange (GBP) and the New York Stock Exchange (USD), reflecting the dual-listed nature of the company.
- Volume Disparity: Charles Bancroft executed the largest single transaction (1,577 ADSs), while other directors purchased significantly smaller quantities (201-202 ADSs).